Vaccinex’s (NASDAQ:VCNX) lock-up period will end on Tuesday, February 5th. Vaccinex had issued 3,333,334 shares in its IPO on August 9th. The total size of the offering was $40,000,008 based on an initial share price of $12.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Several analysts have recently commented on the company. Oppenheimer set a $22.00 price target on Vaccinex and gave the company a “buy” rating in a report on Wednesday, January 16th. Zacks Investment Research cut Vaccinex from a “hold” rating to a “sell” rating in a report on Wednesday, December 26th. Finally, ValuEngine cut Vaccinex from a “buy” rating to a “hold” rating in a report on Friday, January 4th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Vaccinex has a consensus rating of “Buy” and an average target price of $22.00.

VCNX opened at $4.75 on Friday. Vaccinex has a 12 month low of $3.32 and a 12 month high of $12.00.

Vaccinex (NASDAQ:VCNX) last posted its quarterly earnings results on Tuesday, November 13th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.29). The firm had revenue of $0.20 million during the quarter. On average, analysts anticipate that Vaccinex will post -4.46 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of VCNX. Bank of New York Mellon Corp acquired a new position in Vaccinex during the third quarter worth $124,000. Perceptive Advisors LLC acquired a new position in Vaccinex during the third quarter worth $365,000. Nexthera Capital LP acquired a new position in Vaccinex during the third quarter worth $124,000. Vanguard Group Inc. acquired a new position in Vaccinex during the third quarter worth $341,000. Finally, Vanguard Group Inc acquired a new position in Vaccinex during the third quarter worth $341,000. 2.17% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/vaccinex-incs-lock-up-period-to-end-on-february-5th-nasdaqvcnx/2789091.html.

Vaccinex Company Profile

Vaccinex, Inc is a clinical-stage biotechnology company, which engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. It focuses on developing antibody treatments relevant to cancer, inflammation, and auto-immune diseases, as well as products for the treatment of non-small cell lung cancer, osteosarcoma, melanoma and Huntington’s diseases.

Read More: What is a blue-chip stock?

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.